Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nuclear medicine applications for neuroendocrine tumors.
Chatal JF, Le Bodic MF, Kraeber-Bodéré F, Rousseau C, Resche I. Chatal JF, et al. Among authors: rousseau c. World J Surg. 2000 Nov;24(11):1285-9. doi: 10.1007/s002680010213. World J Surg. 2000. PMID: 11038195 Review.
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: rousseau c. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3973S-81S. Clin Cancer Res. 2003. PMID: 14506196 Clinical Trial.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Among authors: rousseau c. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M, Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C, Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF, Campone M. Rousseau C, et al. J Clin Oncol. 2006 Dec 1;24(34):5366-72. doi: 10.1200/JCO.2006.05.7406. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088570 Clinical Trial.
Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.
Curtet C, Carlier T, Mirallié E, Bodet-Milin C, Rousseau C, Barbet J, Kraeber-Bodéré F. Curtet C, et al. Among authors: rousseau c. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1556-62. doi: 10.1007/s00259-007-0393-6. Epub 2007 May 24. Eur J Nucl Med Mol Imaging. 2007. PMID: 17522858 Clinical Trial.
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Oudoux A, et al. Among authors: rousseau c. J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7. doi: 10.1210/jc.2007-0938. Epub 2007 Sep 18. J Clin Endocrinol Metab. 2007. PMID: 17878252 Clinical Trial.
791 results